Table 1

Demographics and baseline clinical characteristics

Placebo (n=41)CAP-1002 group (n=83)P value
Age, mean (SD)53.5 (10.2)54.7 (11.1)0.56
Male gender, n (%)36 (87.8)72 (86.7)0.99
Chronicity of MI, n (%)
 Recent17 (41.5)37 (44.6)0.85
 Chronic24 (58.5)46 (55.4)
Race, n (%)
 White34 (82.9)73 (87.9)0.17
 Black or African-American6 (14.6)7 (8.4)
 Asian03 (3.6)
 American-Indian or Alaska Native1 (2.4)0
Diabetes mellitus, n (%)11 (26.8)18 (21.7)0.65
Hypertension, n (%)27 (65.8)48 (57.8)0.70
ACE inhibitors or ARBs, n (%)35 (85.4)76 (91.6)0.35
Beta blockers, n (%)40 (97.6)79 (95.2)0.99
Diuretics, n (%)18 (43.9)34 (41.0)0.85
Aldosterone antagonists, n (%)12 (29.3)28 (33.7)0.69
Antithrombotic agents, n (%)41(100)81 (97.6)0.99
Lipid lowering agents, n (%)39 (95.1)79 (95.2)0.99
Aspirin, n (%)41(100)78 (93.4)0.17
  • ARB, angiotensin receptor blocker; MI, myocardial infarction.